An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
completed

An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

key information

study id #: NCT02760277

condition: Duchenne Muscular Dystrophy

status: completed

purpose:

The main purposes of this study are to see if it is safe to use a new medication called vamorolone for more than two weeks in children with Duchenne muscular dystrophy (DMD), to see if vamorolone works for the treatment for DMD, and to see how any potential side effects compare to those seen in boys using steroids.

intervention:
Vamorolone 0.25 mg/day/day, Vamorolone 0.75 mg/day/day, Vamorolone 2.0 mg/day/day, Vamorolone 6.0 mg/day/day

mechanism of action: Glucocorticoid to delay decline in muscle strength

results: https://clinicaltrials.gov/ct2/show/results/NCT02760277

last updated: November 22, 2018

study details

start date: August 2016

estimated completion: April 26, 2018

phase of development: Phase 2

size / enrollment: 48

study description:
This study will evaluate if it is safe to use a new medication called vamorolone for more than two weeks in children with DMD, if boys with DMD who take the study medication have improved muscle function compared to boys with DMD in other studies who did not take any type of steroid, and to see if boys with DMD who take the study medication gain less weight compared to boys with DMD in a prior study who took another type of steroid called prednisone. Enrolled participants will take the study medication for 24 weeks.

primary outcomes:

  • Number of participants with treatment-related adverse events as assessed by CTCAE Version 4.03 [ Time Frame: 24 weeks ]
  • Muscle function measured by Time to Stand Test (TTSTAND) [ Time Frame: 24 weeks ]
  • Body size as measured by body mass index (BMI) z-score [ Time Frame: 24 weeks ]

secondary outcomes:

  • Serum pharmacodynamics biomarkers measured by levels of cortisol [ Time Frame: 24 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of ACTH [ Time Frame: 24 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of PINP [ Time Frame: 24 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of osteocalcin [ Time Frame: 24 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of CTX [ Time Frame: 24 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of 17- hydroxyprogesterone [ Time Frame: 24 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of testosterone [ Time Frame: 24 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of corticosterone [ Time Frame: 24 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of 11-deoxycortisol [ Time Frame: 24 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of glucose [ Time Frame: 24 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of insulin [ Time Frame: 24 weeks ]
  • Muscle strength measured by Quantitative Muscle Testing (QMT) [ Time Frame: 24 weeks ]
  • Muscle function measured by Time to Climb Test (TTCLIMB) [ Time Frame: 24 weeks ]
  • Muscle function measured by Time to Run/Walk 10 Meters Test (TTRW) [ Time Frame: 24 weeks ]
  • Muscle function measured by North Star Ambulatory Assessment (NSAA) [ Time Frame: 24 weeks ]

inclusion criteria:
• Participant's parent or legal guardian has provided written informed consent/HIPAA authorization prior to any extension study-specific procedures;
• Participant has previously completed study VBP15-002 up to and including the Week 4 Follow-up assessments within 8 weeks prior to enrollment; and
• Participant and parent/guardian are willing and able to comply with scheduled visits, study drug administration plan, and study procedures.

exclusion criteria:
• Participant had a serious or severe adverse event in study VBP15-002 that, in the opinion of the Investigator, was probably or definitely related to vamorolone use and precludes safe use of vamorolone for the subject in this study;
• Participant has current or history of major renal or hepatic impairment, diabetes mellitus or immunosuppression;
• Participant has current or history of chronic systemic fungal or viral infections;
• Participant has used mineralocorticoid receptor agents, such as spironolactone, eplerenone, canrenone (canrenoate potassium), prorenone (prorenoate potassium), mexrenone (mexrenoate potassium) within 4 weeks prior to the first dose of study medication;
• Participant has evidence of symptomatic cardiomyopathy. [Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary];
• Participant is currently being treated or has received previous treatment with oral glucocorticoids or other immunosuppressive agents. [Notes: Past transient use of oral glucocorticoids or other oral immunosuppressive agents for no longer than 3 months cumulative, with last use at least 3 months prior to first dose of study medication, will be considered for eligibility on a case-by-case basis. Inhaled and/or topical corticosteroids prescribed for an indication other than DMD are permitted but must be administered at stable dose for at least 3 months prior to study drug administration];
• Subject has used idebenone within 4 weeks prior to the first dose of study medication;
• Participant has an allergy or hypersensitivity to the study medication or to any of its constituents;
• Participant has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the Investigator;
• Participant has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator; or
• Participant is currently taking any investigational drug, or has taken any investigational drug other than vamorolone within 3 months prior to the start of study treatment.

study contacts

sponsor: ReveraGen BioPharma, Inc.

investigators: Paula R Clemens, MD

locations: United States, Australia, Canada, Israel, Sweden, United Kingdom